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Free cholesterol accumulation impairs lysosome function
and inhibits autophagic activity in hepatocytes. Induction of
bile acid synthesis attenuates AKT/mechanistic target of
rapamycin (mTOR) signaling, leading to autophagy activation.
Targeting the enterohepatic bile acid signaling by bile acid
sequestrant induces hepatic autophagy in mice.
BACKGROUND & AIMS: Hepatic cholesterol accumulation and
autophagy defects contribute to hepatocyte injury in fatty liver
disease. Bile acid synthesis is a major pathway for cholesterol
catabolism in the liver. This study aims to understand the
molecular link between cholesterol and bile acid metabolism
and hepatic autophagy activity.
METHODS: The effects of cholesterol and cholesterol 7a-hy-
droxylase (CYP7A1) expression on autophagy and lysosome
function were studied in cell models. The effects and mecha-
nism of disrupting enterohepatic bile acid circulation on
hepatic autophagy were studied in mice.
RESULTS: The results ﬁrst showed differential regulation of
hepatic autophagy by free cholesterol and cholesterol ester,
whereby a modest increase of cellular free cholesterol, but not
cholesterol ester, impaired lysosome function and caused
marked autolysosome accumulation. We found that CYP7A1
induction, either by cholestyramine feeding in mice or
adenovirus-mediated CYP7A1 expression in hepatocytes, caused
strong autophagy induction. Mechanistically, we showed that
CYP7A1 expression markedly attenuated growth factor/AKT
signaling activation of mechanistic target of rapamycin (mTOR),
but not amino acid signaling to mTOR in vitro and in vivo.
Metabolomics analysis further found that CYP7A1 induction not
only decreased hepatic cholesterol but also altered phospholipid
and sphingolipid compositions. Collectively, these results
suggest that CYP7A1 induction interferes with growth factor
activation of AKT/mTOR signaling possibly by altering mem-
brane lipid composition. Finally, we showed that cholestyramine
feeding restored impaired hepatic autophagy and improved
metabolic homeostasis in Western diet–fed mice.
CONCLUSIONS: This study identiﬁed a novel CYP7A1–AKT–
mTOR signaling axis that selectively induces hepatic autophagy,
which helps improve hepatocellular integrity and metabolic
homeostasis. (Cell Mol Gastroenterol Hepatol 2016;-:-–-;
http://dx.doi.org/10.1016/j.jcmgh.2016.10.002)Keywords: Cholesterol; Cholestyramine; Fatty Liver; Nuclear
Receptor.
merging evidence supports that nonesteriﬁed freeEcholesterol (FC) accumulates in fatty livers and
contributes to hepatocyte injury.1–4 Impaired hepatic
cholesterol homeostasis further contributes to dyslipidemia,
atherosclerosis, and a higher risk of cardiovascular disease.5
Hepatic cholesterol homeostasis is coordinately controlled
by input and elimination pathways. The sterol response
element binding protein-2 (SREBP-2)–mediated endoplasmic
reticulum (ER) cholesterol-sensing mechanism regulates
cellular cholesterol input pathways.6 A decrease of ER
cholesterol leads to proteolytic cleavage activation of
SREBP-2, which induces the expression of 3-hydroxy-3-
methylglutaryl-coenzyme A-CoA reductase (HMGCR) and
low-density lipoprotein receptor (LDLR) to increase
intracellular cholesterol levels. On the other hand, bile acid
synthesis is the major cholesterol elimination pathway. The
cholesterol 7a-hydroxylase (CYP7A1) is an ER resident
enzyme that catalyzes the ﬁrst and rate-limiting step in the
conversion of cholesterol into bile acids.7 Bile acid synthesis
has a major impact on ER cholesterol content, and CYP7A1
induction can activate the entire SREBP-2–regulated tran-
scriptional network to regulate cellular cholesterol meta-
bolism in the liver.8 This ER cholesterol-sensing mechanism
is the molecular basis for the cholesterol-lowering drugs
statins and bile acid sequestrants. In addition, a number of
studies have suggested that nutrient signaling regulation of
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metabolic homeostasis.9–11
Autophagy is a well-conserved cellular self-degradation
system that eliminates protein aggregates and damaged
organelles to help maintain cellular integrity.12 Autophagy is
also a catabolic process that generates nutrients and energy
by degrading macromolecules in response to nutrient
deprivation.13 The nutrient-sensing mechanistic target of
rapamycin (mTOR) signaling plays a key role in regulating
autophagy activity in response to changes of nutrient
availability.13 A hepatic autophagy defect exacerbated
hepatocyte injury in fatty liver diseases.14–16 Furthermore,
obesity and fatty liver are associated with defective hepatic
autophagy, possibly owing to hyperinsulinemia, lipid
accumulation, and impaired vesicle fusion.17–19
Recent clinical and basic research have shown that
targeting the enterohepatic bile acid signaling by bile acid
sequestrants or the selective apical sodium-dependent bile
acid transporter inhibitors represents a promising thera-
peutic strategy for decreasing plasma cholesterol and
improving insulin sensitivity in diabetes and fatty liver
disease, and attenuating bile acid toxicity in cholestasis.20–23
However, the highly complex changes of hepatic and intes-
tinal metabolic and signaling pathways caused by disrupting
enterohepatic bile acid circulation still are incompletely
understood. In this study, we show that free cholesterol
accumulation is a major causal factor for liver autophagy
impairment, and that targeting the enterohepatic bile acid
signaling is an effective approach to induce hepatic auto-
phagy via a novel CYP7A1–AKT–mTOR signaling cascade,
which is potentially beneﬁcial in improving hepatocellular
integrity and metabolic homeostasis.
Materials and Methods
Reagents
Antibodies against microtubule-associated protein
1A/1B-light chain 3 (LC3B), phospho- and total tibosomal
protein S6 (S6) (S240/244), eukaryotic translation initiation
factor 4E-binding protein 1 (4EBP-1) (T37/46), AKT (S473),
glycogen synthase kinase 3b (GSK3b) (S9), and histone 3
were purchased from Cell Signaling Technology (Danvers,
MA). P62 antibody was purchased from Abnova (Walnut,
CA). Actin antibody, water-soluble cholesterol (in methyl-b-
cyclodextrin), cholestyramine (ChTM), acyl-CoA:cholesterol
acyltransferase (ACAT) inhibitor Sandoz 58-035 chloro-
quine, and cholestyramine were purchased from Sigma
(St. Louis, MO). Lysotracker red and anti-SREBP-2 antibody
were from Thermo Scientiﬁc (Grand Island, NY). Highly
puriﬁed human LDL was purchased from Lee Biosolutions
(Maryland Heights, MO). The mCherry-galectin expression
vector was described previously.24 Lipoprotein-depleted
serum was purchased from Kalen Biomedical, LLC.
Animals
Male 8- to 10-week-old C57BL/6J mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). The Western
diet (TD.88137; Harlan Teklad, East Millstone, NJ) contains
42% fat calories and 0.2% cholesterol. ChTM was mixed withdiets (2%, wt/wt). For confocal microscopy, mice were
injected with Ad-RFP-GFP-LC3 at 108 pfu/mouse via tail vein
3 days before death. All mice were fasted for 6 hours starting
from approximately 6 AM and killed. All animals received
humane care according to the criteria outlined in the Guide for
the Care and Use of Laboratory Animals. All protocols were
approvedby the InstitutionalAnimal Care andUse Committee.
Cell Culture and Treatments
HepG2 cells were purchased from ATCC (Manassas, VA).
Cells were maintained in Dulbecco’s modiﬁed Eagle medium
supplemented with 10% fetal bovine serum or in Dulbecco’s
modiﬁed Eagle medium containing lipoprotein-depleted
serum as indicated. Experiments were initiated when cells
were 60%–80% conﬂuent. Primary human hepatocytes
were obtained from the Cell Isolation Core at Kansas
University Medical Center and treatment was started within
24 hours after the cells were plated.
Measurement of Mitochondria Bioenergetic
Function
All XF assays were performed with an XF24–3 Extracel-
lular Flux Analyzer (Seahorse Bioscience, North Billerica,
MA). Mitochondria from mouse livers were isolated by dif-
ferential centrifugation methods as described previously.25
Mitochondria from 4 mice per group were pooled and the
assays were performed in triplicate. Isolated liver mito-
chondria in mitochondrial assay solution (1 mitochondrial
assay solution: 70mmol/L sucrose, 220mmol/Lmannitol, 10
mmol/L KH2PO4, 5 mmol/L MgCl2, 2 mmol/L HEPES, 1
mmol/L ethylene glycol-bis(b-aminoethyl ether)-N,N,N0,N0-
tetraacetic acid, and 0.2% [wt/vol] fatty acid–free bovine
serum albumin, pH 7.2 at 37C) containing substrate (10
mmol/L succinate þ 2 mmol/L rotenone) was plated. The
sensor cartridge was loaded with port A, adenosine diphos-
phate (4 mmol/L ﬁnal); port B, oligomycin (2.5 mg/mL ﬁnal);
port C, FCCP (4 mmol/L ﬁnal); and port D, antimycin A (4
mmol/L ﬁnal) to measure the bioenergetic proﬁle. The
respiration was measured in a coupled state in the presence
of substrate (basal respiration), followed by state 3 (phos-
phorylating respiration, in the presence of adenosine
diphosphate and substrate), state 4 (resting respiration) after
conversion of adenosine diphosphate to adenosine triphos-
phate, state 4o (inducedwith the addition of oligomycin), and
then maximal uncoupler-stimulated respiration (state 3u).
Metabolomics Analysis
The metabolomics analysis was performed by Metabolon,
Inc (Durham, NC). Brieﬂy, liver samples (n ¼ 5) were pre-
pared using the automated MicroLab STAR system from
Hamilton Company (Reno, NV). Several recovery standards
were added based on tissue weight before sample extraction
for data normalization. The extract was analyzed on aWaters
Acquity UPLC (Milford, MA) and a Thermo Scientiﬁc Q-
Exactive high-resolution/accurate mass spectrometer inter-
faced with a heated electrospray ionization source and
Orbitrap mass analyzer (Grand Island, NY). Raw data were
extracted, peak-identiﬁed, and processed using Metabolon’s
- 2016 Bile Acid Sequestrant Induces Hepatic Autophagy 3reference library and software. Peaks were quantiﬁed using
the area under the curve.
Immunoblot
Cell or liver homogenates were incubated in 1 RIPA
buffer containing 1% sodium dodecyl sulfate and protease
inhibitor cocktail for 1 hour on ice, followed by sonication and
centrifugation. Supernatant were used for sodium dodecyl
sulfate–polyacrylamide gel electrophoresis. Densitometrywas
performedwith ImageJ software (National Institutes ofHealth,
Bethesda, MD). The band intensity (normalized to actin) of 3
experiments was expressed as means ± SD values that were
placed below the representative blot.
Confocal Microscopy
Cells were plated in one 10-cm culture dish. In some ex-
periments, cells were infected with adenoviral vectors or
transfectedwith plasmids, and then plated on chamber slides.
Mice were injected with Ad-RFP-GFP-LC3 at 108 pfu/mouse
via tail vein. After 3 days, mice were fasted for 6 hours since 6
AM and then killed. Cells and liver tissues were ﬁxedwith 4%
paraformaldehyde. Images were acquired with a Leica DM
5500 confocal microscope (Buffalo Grove, IL).
Electron Microscopy
Fresh liver tissue was ﬁxed in 2% glutaraldehyde
followed by 1% OsO4. After dehydration, sections were
stained with uranyl acetate and lead citrate. Images were
taken with a JEM 1016CX electron microscope (Peabody,
MA) as previously described.26
RNA Isolation and Quantitative Real-Time
Polymerase Chain Reaction
Total RNA was isolated with Tri-reagent (ThermoFisher
Scientiﬁc, Grand Island, NY). Real-time polymerase chain
reaction were performed with primers and SYBR master
mix (Bio-Rad, Hercules, CA). Ampliﬁcation of 18S was used
as an internal control. Relative messenger RNA (mRNA)
expression was quantiﬁed using the comparative Ct method
and expressed as 2DDCt.
Lipids and Glucose Analysis
Lipids were extracted in chloroform:methanol (2:1,
vol/vol). Total cholesterol and triglyceride levels were
measured with assay kits (Pointe Scientiﬁc, Canton, MI).
Free cholesterol was measured with an assay kit from
Thermo Scientiﬁc. The cholesterol ester value was obtained
by subtracting free cholesterol from total cholesterol in the
same sample. Blood glucose was measured with the
Onetouch Ultra glucose monitor (LifeScan, Wayne, PA).
Recombinant Adenovirus
The construction and use of adenovirus expressing tandem
RFP-GFP-LC3B for the study of autophagy ﬂux was described
previously.27 Adenovirus expressing the rat Cyp7a1 gene was
a generous gift from Dr William Michael Pandak (Virginia
Commonwealth University, Richmond, VA).28 Ad-null waspurchased fromVectorBiolabs (Philadelphia, PA). Ad-GFPwas
from Dr Li Wang (University of Connecticut, Storrs, CT).
Cathepsin B Activity Assay
As described previously,29 cells or liver tissues were
lysed in M2 buffer (50 mmol/L Tris, pH 7.5, 130 mmol/L
NaCl, 10% glycerol, 0.5% NP-40, 0.5 mmol/L EDTA, and 0.5
mmol/L ethylene glycol-bis[b-aminoethyl ether]-N,N,N0,N0-
tetraacetic acid in dH2O) without protease inhibitors.
Protein lysates then were incubated with cathepsin B
ﬂuorogenic substrate z-RR-AMC and ﬂuorescence intensity
was determined using a Tecan Inﬁnite M200 Pro plate
reader (Morrisville, NC). L-leucyl-L-leucine methyl ester,
which accumulates in lysosomes and causes lysosome
impairment, was used as a positive control.
Statistical Analysis
Results were expressed as means ± SE for animal
studies. Statistical analysis was performed with the Student
t test or analysis of variance. A P value less than .05 was
considered statistically signiﬁcant.
Access to Data
All authors had access to all the data and have reviewed
and approved the ﬁnal manuscript.
Results
Hepatic Autophagy Is Highly Sensitive to
Inhibition by Cellular FC Loading, but not
LDL Loading
We ﬁrst subjected HepG2 cells to FC loading for 16 hours
and measured LC3B in an autophagic ﬂux assay. FC loading
dose-dependently increased LC3B-II and p62 protein, but
did not increase LC3B-II and p62 further in the presence of
chloroquine (CQ) (Figure 1A), suggesting autophagy inhibi-
tion at the lysosomal level. It is known that FC loading ﬁrst
enriches the plasma membrane (PM) cholesterol pool, and
excessive FC is delivered to other intracellular organelles
including the ER where excessive FC is esteriﬁed to
cholesterol ester (CE) by the ACAT for cytosolic storage.30
LC3B-II and p62 accumulation was enhanced markedly in
the presence of ACAT inhibitor (Figure 1A). In comparison,
treatment of puriﬁed human LDL, which contained pri-
marily CE, caused very modest increases of LC3B-II abun-
dance with or without the presence of an ACAT inhibitor
(Figure 1B). Similar results were obtained when cells were
cultured in medium containing lipoprotein-depleted serum
(not shown). The FC-induced LC3B-II accumulation was
reproduced in primary human hepatocytes (Figure 1C).
Treating HepG2 cells with the same concentration of the
vehicle (methyl-b-cyclodextrin) did not affect LC3 and p62
protein (data not shown). FC or LDL loading did not alter
the mRNA of key autophagy genes ULK1, autophagy protein
5, autophagy protein 7, and LC3B, except that LDL loading
increased p62 mRNA by approximately 3-fold (data not
shown), which may contribute partially to increased p62
protein levels (Figure 1B).
Figure 1. Free cholesterol
caused rapid LC3B accu-
mulation. (A and B) West-
ern blot: HepG2 cells were
cultured in 10% fetal
bovine serum and treated
with the indicated concen-
trations of cholesterol and
puriﬁed human LDL with or
without ACAT inhibitor
(12.5 mg/mL) for 16 hours.
Some cells were treated
with CQ (50 mmol/L) during
the last 6 hours as indi-
cated. LE, long exposure;
SE, short exposure. (C)
Primary human hepato-
cytes (PHH) were treated
with free cholesterol for 16
hours. Some cells were
treated with CQ (50 mmol/
L) during the last 6 hours.
(D) HepG2 cells or primary
human hepatocytes were
treated with 50 mg/mL
cholesterol for up to 8
hours. LC3B and actin
protein levels were
measured by Western blot.
(E) HepG2 cells were pre-
treated with 50 mmol/L CQ
for 0.5 hours, followed by
cholesterol treatment for
an additional 5 hours.
*Statistical signiﬁcance vs
control.
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cells to FC loading in a short-term time course. FC loading
time-dependently caused LC3B-II to accumulate over the
course of 8 hours in HepG2 cells and human hepatocytes
(Figure 1D). At the 5-hour time point, FC loading did not
increase LC3B-II and p62 further in the presence of CQ in an
autophagic ﬂux assay, which conﬁrmed rapid autophagy
inhibition (Figure 1E). Because FC loading for 8 hours
already caused LC3B accumulation (Figure 1D), we there-
fore measured cellular cholesterol levels at the 8-hour time
point. FC loading at both 12.5 and 25 mg/mL increased
cellular FC by approximately 20%, and increased cellular CE
by approximately 25% and approximately 65%, respec-
tively, and resulted in a dose-dependent increase of LC3B
levels (Figure 2A). In contrast, LDL loading increased
cellular CE by approximately 40%, but did not result in a
corresponding increase in cellular FC content unless ACAT
was inhibited simultaneously (Figure 2B). LDL loading
caused a very mild increase of LC3B, which was not affectedfurther by ACAT inhibitor despite an FC increase by
approximately 15% (Figure 2B). These results indicate that
LDL uptake, lysosomal LDL CE hydrolysis, and lysosomal FC
transport are highly coordinated processes. Some of these
steps, such as LDLR down-regulation, may be rate-limiting
to maintain cellular cholesterol levels relatively constant.
Nevertheless, addition of ACAT inhibitor completely pre-
vented CE increase but increased FC further by an addi-
tional approximately 30%, and led to further LC3B-II
accumulation in FC-treated cells (Figure 2B). These results
provide important evidence to support that autophagy in-
hibition was owing primarily to cellular FC accumulation.FC Accumulation Impairs Lysosomal Function
and Inhibits Autophagy
To obtain further insights on the molecular basis of FC-
induced LC3B-II accumulation, we next studied autophagic
ﬂux in HepG2 cells expressing a tandem RFP-GFP-LC3B
Figure 2. Free cholesterol
impaired autolysosome
clearance. (A and B)
HepG2 cells were treated
with cholesterol, LDL or
ACAT inhibitor (12.5 mg/
mL) for 8 hours as indi-
cated. Cellular cholesterol
and LC3B protein levels
were measured. Choles-
terol assays were repeated
in triplicates. Results are
expressed as means ± SD.
*Statistical signiﬁcance vs
untreated controls. Statis-
tical signiﬁcance vs 25 mg/
mL cholesterol treated. (C)
Confocal microscope:
HepG2 cells were infected
with Ad-RFP-GFP-LC3B at
a multiplicity of infection of
approximately 0.5 for 16
hours. Cells then were
treated with cholesterol
with or without ACAT in-
hibitor (12.5 mg/mL) for 16
hours, with CQ (50 mmol/L)
for 6 hours. Scale bar: 30
mm. DAPI, 40,6-diamidino-
2-phenylindole.
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preferentially was quenched in autolysosomes, and thus red
puncta mainly represented fused autolysosomes, and
merged yellow puncta mainly represented autophago-
somes.31 This was ﬁrst validated by amino acid starvation
and by CQ treatment (Figure 2C). FC-treated cells had an
increased number of yellow puncta (Figure 2C). A signiﬁcant
number of these yellow puncta were found to be associated
closely with enlarged red puncta, which was especially
prominent in cells treated with 50 mg/mL FC. Because
yellow puncta are thought to represent autophagosomes,
these results suggest autophagosome accumulation is owing
to defective autophagosome fusion with lysosomes because
lysosome function may be impaired by FC accumulation.In addition, it also is possible that decreased autolysosome
clearance efﬁciency may contribute to the accumulation of
yellow and red puncta in these cells. In support of this
hypothesis, we showed that FC loading for 8 hours caused
enlarged lysotracker red–positive puncta and enlarged
Lamp1-positive puncta, which represent acidic late endo-
cytic compartments including autolysosomes (Figure 3A).
Furthermore, FC loading signiﬁcantly decreased lysosome
function as evidenced by both reduced cathepsin B activity
(Figure 3B) and attenuated intracellular DQ-BSA hydrolysis
(Figure 3C). In contrast, LDL loading dose-dependently
increased cathepsin B activity (Figure 3B), which we spec-
ulate was because LDL endocytosis increased the total
number of late endosomes/lysosomes. To gain further
Figure 3. Free cholesterol loading impaired lysosome function. (A) HepG2 cells were treated with cholesterol for 8 hours, and
stained with either Lamp1 or lysotracker red. Scale bar: 10 mm. (B) Cathepsin B activity was determined in HepG2 cells treated
with the indicated concentration of cholesterol or LDL for 16 hours. L-leucyl-L-leucine methyl ester (LLOMe) was used as a
positive control. Assays were repeated in triplicates. Results are expressed as means ± SD. *Statistical signiﬁcance vs
untreated controls. (C) DQ-BSA assay in HepG2 cells treated with 25 mg/mL cholesterol for 16 hours. LLOMe was used as a
positive control. (D) HepG2 cells were transfected with plasmids expressing mCherry–galactin-3. Confocal imaging of
mCherry–galectin-3 and Lamp1 co-localization (indicated by white arrows) in HepG2 cells treated with 25 mg/mL cholesterol or
0.5 mg/mL LDL for 16 hours. LLOMe was used as a positive control. Scale bar: 30 mm. (E) HepG2 cells transfected with
plasmids expressing mCherry–galactin-3 and GFP-LC3 were treated with 0.5 mg/mL LDL or 25 mg/mL cholesterol for 16
hours, and images were taken with a confocal microscopy. Scale bar: 10 mm. (F) HepG2 cells were treated with cholesterol or
LDL with or without ACAT inhibitor for 16 hours. Cleaved caspase 3 was detected in Western blot. Chol, cholesterol.
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evaluated lysosome membrane permeabilization (LMP) in
cells expressing mCherry-tagged galectin 3, a cytosolic and
nuclear protein that localizes to the lysosomes upon LMP.24
FC loading induced galectin-3–positive puncta thatco-localized with Lamp1-positive puncta (Figure 3D), sug-
gesting that FC loading induced LMP. Furthermore, galectin-
3 also co-localized with LC3B-positive puncta (Figure 3E),
indicating that FC loading also might damage the GFP-
LC3–positive vesicle structures. Unexpectedly, LDL loading
- 2016 Bile Acid Sequestrant Induces Hepatic Autophagy 7also induced galectin-3 localization to Lamp1-positive
puncta and LC3-positive puncta (Figure 3D and E). We
speculate that the presence of LDL-derived FC in some late
endocytic compartments may cause some degree of LMP
and galectin-3 recruitment. However, only FC loading at
50 mg/mL caused weak caspase-3 cleavage, which was
enhanced markedly in the presence of ACAT inhibitor
(Figure 3F).CYP7A1 Induction Increased Hepatic Autophagy
Bile acid synthesis is the major ER cholesterol catabolic
mechanism speciﬁc to hepatocytes. Given that autophagywas
highly sensitive to cellular FC increase, we next asked if active
removal of intracellular FC via stimulating bile acid synthesis
could modulate autophagy in the liver. To address this
question, we fed mice a ChTM-containing chow diet for a
short period of 6 days, which reduced most species of tauro-
conjugated bile acids in the liver (Figure 4A). ChTM feeding
increased liver CYP7A1 and CYP8B1 mRNA and decreased
farnesoid X receptor target gene small heterodimer partner
(SHP) mRNA (Figure 4C). ChTM feeding signiﬁcantly
decreased FC by approximately 15% and increased bile acid
synthesis intermediates 7-hydroxycholesterol and
7a-hydroxy-3-oxo-4-cholestenoate (Figure 4B). CYP7A1 in-
duction caused ER cholesterol depletion as evidenced by
SREBP-2 cleavage and higher HMGCR and LDLRmRNA levels
(Figure 4C and D). SREBP-2 precursor was not detected by
the antibody used. Under these conditions, ChTM resulted in
approximately 5-fold higher LC3B-II protein without p62
protein accumulation in mouse livers (Figure 4E). Further-
more, electron microscopy analysis showed signiﬁcantly
increased numbers of double-membrane autophagosomes in
the liver of ChTM-fed mice (Figure 4F). ChTM feeding did not
induce the mRNA levels of key autophagy genes (Figure 4C),
suggesting that ChTM induction of autophagy was indepen-
dent of transcriptional control of autophagy genes.
We next measured liver mTOR signaling, which is a
master regulator of autophagy initiation. The liver phos-
phorylation levels of mTOR targets S6 and 4EBP-1 decreased
by approximately 50% in ChTM-fed mice (Figure 5A). We
also found that the basal phosphorylation levels of AKT and
GSK3b, an AKT target, were signiﬁcantly lower in ChTM-fed
mice (Figure 5A). These results provide a signaling basis that
linked increased autophagy to decreased mTOR activity in
ChTM-fed mice. To distinguish if autophagy induction by
ChTM was a result of increased CYP7A1 expression or
decreased hepatic bile acid concentration, we next turned to
CYP7A1 overexpressing HepG2 cells in vitro. As expected,
overexpression of a rat CYP7A1 in HepG2 cells increased
SREBP-2 mature form as well as the mRNA of HMGCR and
LDLR (Figure 5B and C).28 CYP7A1 overexpression markedly
induced autophagic ﬂux in both HepG2 cells and primary
human hepatocytes (Figure 5D and E). Consistent with our
in vivo observation in ChTM-fed mice, CYP7A1 over-
expression markedly decreased phosphorylation of S6 and
4EBP-1 (Figure 5F). Taken together, these results showed an
interesting link between cellular CYP7A1 induction and
mTOR signaling that controls autophagy activity.CYP7A1 Induction Attenuated Growth Factor
Signaling to mTOR, but not Amino Acid
Signaling to mTOR
Growth factor signaling from the cell surface and amino
acid signaling on the lysosomes are 2 major nutrient-
sensing mechanisms activating mTOR,13 and thus were
investigated further. We ﬁrst determined if changes in
mTOR signaling were linked to changes in cellular choles-
terol levels, and found FC loading time-dependently
enhanced the phosphorylation of S6 and 4EBP1, as well as
AKT and its target GSK3b (Figure 6A and B). These choles-
terol stimulatory effects on AKT and mTOR signaling largely
were prevented by CYP7A1 overexpression (Figure 6B).
These results were in line with several recent studies
showing that cellular cholesterol abundance and cholesterol
PM trafﬁcking are essential in insulin/AKT signaling
activation via proposed lipid raft microdomains.32,33 Indeed,
we found that CYP7A1 overexpression also could attenuate
insulin-induced phosphorylation of AKT, GSK3b, and S6 in
HepG2 cells (Figure 6C). In contrast, CYP7A1 overexpression
did not prevent amino acid reactivation of mTOR
(Figure 6D) or amino acid–induced mTOR recruitment to
the Lamp1-positive puncta (Figure 6E). These results
support that increasing CYP7A1 expression induces auto-
phagy via attenuating AKT signaling to mTOR from the cell
surface but independent of interference with amino acid
signaling to mTOR on the lysosomes.
Finally, we asked if ChTM-induced cholesterol reduction
indirectly could alter liver phospholipids and sphingolipids
that also modulate cellular signal transduction. We noticed
that the major phosphoatidylcholine and phosphoatidyle-
thanolamine species (C16:0/C18:1 and C18:0/C18:1) were
decreased in the liver of ChTM-fed mice (Figure 7A).
Furthermore, phosphoatidylinositol, which serves as the
substrates for phosphatidylinositol 3 kinase, showed a
consistent trend of decreasing (Figure 7A). In contrast, most
of the sphingomyelin species, which are known to interact
with a special pool of cholesterol in the PM, were increased
signiﬁcantly in the liver of ChTM-fed mice (Figure 7B). Liver
C16:0 ceramides were not altered (Figure 7B), and no
corresponding changes in major fatty acid species were
noticed (Figure 7C).
Cholestyramine Feeding Improved Metabolic
Homeostasis and Restored Hepatic Autophagy in
Diet-Induced Obesity Mice
In the last set of experiments, we tested if CYP7A1
induction by ChTM could restore hepatic autophagy in diet-
induced obesity (DIO) mice. Adding ChTM to a Western diet
largely prevented DIO (Figure 8A). Accordingly, ChTM
signiﬁcantly attenuated hepatic steatosis and hypercholes-
terolemia (Figure 8B–E). It is worth noting that Western diet
feeding markedly enriched the hepatic CE pool, but only
increased hepatic FC by approximately 40% (Figure 8D),
further supporting the critical role of ACAT in preventing
hepatic FC accumulation. It has been reported that FC
accumulation can cause mitochondrial dysfunction.2
DIO mice showed decreased mitochondrial bioenergetic
Figure 4. ChTM feeding
induced hepatic autophagy
in lean mice. Male C57BL/
6J mice were fed a chow
diet or a chow diet contain-
ing 2%ChTM for 6 days. All
micewerebrieﬂy fasted for 6
hours starting at 6 AM and
then killed. (A and B)
Hepatic tauro-conjugated
bile acids, cholesterol,
7-hydroxycholesterol
(7-HOC), and 7a-hydroxy-
3-oxo-4-cholestenoate (7-
HOCA). All results are
expressed as means ± SE
(n ¼ 5). *Statistical signiﬁ-
cance vs chow-fed con-
trols. CA, cholic acid;
CDCA, chenodeoxycholic
acid; DCA, deoxycholic
acid; LCA, lithocholic acid;
MCA, muricholic acid; T,
tauro; UDCA, ursodeox-
ycholic acid. (C) Hepatic
mRNA expression. (D) He-
patic SREBP-2 mature pro-
tein. (E) Hepatic LC3B, P62,
and actin protein levels. (F)
Electron microscopy anal-
ysis of liver sections. N,
nucleus; M, mitochondria.
Arrows denote double-
membrane autophago-
somes. Scale bar: 500 nm.
Right: average number of
autophagosomes per im-
age area at 3000 magniﬁ-
cation from5–10 imagesper
group. A representative im-
age from each group is
shown. AUC, area under the
curve.
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chondrial bioenergetic function (Figure 8F).
Current studies suggest that hepatic autophagy may be
impaired at both initiation and lysosome fusion steps in
obesity and fatty livers.17–19 We found that DIO mice had
quantitatively less hepatic LC3B protein and higher P62
protein levels (Figure 9A). ChTM feeding increased LC3B-II
protein but did not alter p62 protein compared with that
of DIO mice (Figure 9A). We attempted to evaluate in vivo
hepatic autophagic ﬂux in mice by intraperitoneal injection
of CQ, but this approach failed to increase liver LC3B or
p62 levels (not shown). An alternative approach to analyze
hepatic autophagic ﬂux in RFP-GFP-LC3B–expressing mice
found that the liver sections from ChTM-fed mice showed
a signiﬁcantly increased number of red puncta but anunaltered number of yellow puncta (Figure 9B), which
suggests increased autophagy ﬂux. Gene expression anal-
ysis showed that hepatic SREBP-2, HMGCR, and LDLR
mRNA levels were repressed in DIO mice as a result of
cholesterol accumulation, and were induced in ChTM-fed
mice as a result of CYP7A1 induction (Figure 9C). The
mRNA levels of key autophagy genes were decreased
signiﬁcantly by approximately 30%–50% in DIO mice. The
mRNA expressions of many autophagy genes were higher
in ChTM-fed mice, especially in 3-week ChTM-fed mice
(Figure 9C). Recent studies have reported farnesoid X re-
ceptor regulation of autophagy gene transcription.34,35 The
involvement of this mechanism may be ruled out because
ChTM feeding did not affect autophagy gene mRNA levels
in chow-fed mice (Figure 4C).
Figure 5. CYP7A1 overexpression attenuated AKT/mTORsignaling and induced autophagy ﬂux in vitro. (A) Male C57BL/6Jmice
were fed a chow diet or a chow diet containing 2% ChTM for 6 days. Hepatic phosphorylated and total S6, 4EBP-1, AKT, and
GSK3b. *Statistical signiﬁcance vs Chow. (B and C) HepG2 cells were infected with Ad-null or Ad-CYP7A1 at a multiplicity of
infection of 10 for 16 hours, andmRNAexpression andSREBP-2mature protein levelsweremeasured. *Statistical signiﬁcance vs
Ad-Null. (D) Confocal microscopy: HepG2 cells were infected with Ad-RFP-GFP-LC3B at a multiplicity of infection of approxi-
mately 0.5 and Ad-CYP7A1 or Ad-null at a multiplicity of infection of 10 for 16 hours. Puncta number was quantiﬁed manually in
approximately 50 cells. Results are expressed asmeans ± SE. *Statistical signiﬁcance vs controls. Scale bar: 10 mm. (E) Western
blot: primary human hepatocytes (PHH) or HepG2 cells were infected with Ad-null or Ad-CYP7A1 at a multiplicity of infection of
approximately 10 for 16 hours. Some cells thenwere treatedwith CQ (50 mmol/L) for an additional 6 hours. LE, long exposure; SE,
short exposure; H3, histone 3, as loading control. *Statistical signiﬁcance vs Ad-Null. #Statistical signiﬁcance vs Ad-NullþCQ. (F)
HepG2 cellswere infectedwith Ad-null or Ad-CYP7A1 at amultiplicity of infection of 10 for 16 hours in serum-containingmedium.
Phosphorylated and total S6 and 4EBP-1 were measured. DAPI, 40,6-diamidino-2-phenylindole.
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This study shows the differential impacts of FC and CE
accumulation on hepatic autophagy and lysosome function,
and provides mechanistic understanding of how FCaccumulation causes autophagy defect in hepatocytes. PM is
a major reservoir for cellular FC and intracellular membrane
structures contain much less FC.36 Altered membrane lipid
content was suggested to interfere with autophagic
Figure 6. CYP7A1 overexpression attenuated insulin signaling to mTOR. (A) HepG2 cells were cultured in serum-containing
medium and treated with 50 mg/mL cholesterol for up to 8 hours. P/T, the ratio of phosphorylated and total protein was
calculated based on densitometry. *Statistical signiﬁcance vs untreated controls. (B) Cells were infected with Ad-Null
or Ad-CYP7A1 at a multiplicity of infection of 10 for 16 hours in serum-containing medium. Some cells were treated with
50 mg/mL cholesterol for the indicated time. *Statistical signiﬁcance vs Ad-Null at 0 hours. (C) HepG2 cells were infected with
Ad-Null or Ad-CYP7A1 at a multiplicity of infection of 10 for 16 hours in serum-containing medium. All cells were cultured in
serum-free medium for 8 hours ﬁrst, and some cells then were treated with 10 nmol/L insulin for 30 minutes. *Statistical
signiﬁcance vs Ad-Nullþvehicle. #Statistical signiﬁcance vs Ad-Nullþinsulin. (D and E) HepG2 cells were infected with Ad-null
or Ad-CYP7A1 at a multiplicity of infection of 10 for 16 hours in serum-containing medium. Cells then were amino acid–starved
by culturing in Earle’s Balanced Salt Solution (EBSS) for 2 hours. Amino acids (mixture of essential and nonessential amino
acids) then were added back for 30 minutes. (D) Phosphorylated and total S6 and 4EBP1 were measured by Western blot.
*Statistical signiﬁcance vs Ad-Null. (E) Co-localization of Lamp1 and mTOR was studied by confocal microscopy. Chol,
cholesterol. (Inset) Boxed sections in merged images.
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Figure 7. ChTM altered
hepatic phospholipid and
sphingolipid proﬁles in
mice. (A–C) Male C57BL/6J
micewere fed achowdiet or
a chow diet containing 2%
ChTM for 6 days. All mice
were brieﬂy fasted for 6
hours starting at 6 AM and
then killed. Liver phospho-
lipids, sphingolipids, and
fatty acids were determined
by metabolomics analysis.
PC, phosphoatidylcholine;
PE, phosphoatidylethanol-
amine; PtdIns, phosphoati-
dylinositol. Results are
expressed as means ± SE
(n ¼ 5). *Statistical signiﬁ-
cance vs chow-fed
controls.
- 2016 Bile Acid Sequestrant Induces Hepatic Autophagy 11vesicular fusion,19 but how cellular cholesterol impacts
autophagy in hepatocytes still is not fully clear. Our data
suggest that FC accumulation did not stimulate autophagic
ﬂux, did not signiﬁcantly block autophagosome/lysosome
fusion, but primarily impaired autolysosome function and
clearance, as evidenced by morphologic changes of autoly-
sosomes, decreased autolysosome hydrolytic activity,
LC3B-II accumulation, and increased LMP. It was intriguing
that a very small increase of total cellular FC signiﬁcantly
can inhibit autophagy, especially when ACAT-mediated
cholesterol esteriﬁcation was blocked. Given that most
intracellular organelles are relatively “cholesterol-poor,”36 a
modest increase or depletion of cellular FC, such as by
10%–20% as observed by this study, may have a much
more dramatic impact on intracellular organelle FC content.
In addition, our ﬁnding in hepatocytes is in contrast to
previous ﬁndings in macrophages where cholesterol accu-
mulation was shown to induce autophagy to attenuate
cholesterol toxicity by increasing cholesterol efﬂux and
sphingomyelin synthesis,37,38 suggesting a cell type–speciﬁcresponse to cholesterol. Under pathologic conditions in
which hepatic cholesterol homeostasis severely was
impaired, FC accumulation may damage organelles, impair
autophagy, and sensitize the hepatocyte to injury.
Another major ﬁnding from this study was the identiﬁ-
cation of a novel link between CYP7A1 induction, mTOR
signaling, and autophagy activity, which seemed to depend
on cellular cholesterol catabolism. Our results are in line
with the recently reported link between cellular cholesterol
trafﬁcking and mTOR activation, although experimental
methods that reduced cellular cholesterol also impaired
mTOR activation in nonliver cells.39,40 Another recent study
showed that inhibiting Niemann–Pick-type C1- like 1 by
ezetimibe caused lysosome FC accumulation, reduced mTOR
recruitment to the lysosomes, and activated autophagy in
hepatocytes and the small intestinal epithelia.41 However,
although we initially speculated that CYP7A1 induction
possibly may alter lysosome membrane cholesterol and
subsequently decrease lysosomal mTOR localization and
activation, it did not turn out to be the case. In contrast, we
Figure 8. ChTM improved
metabolic homeostasis in
Western diet–fed mice.
Male C57BL/6J mice were
fed chow diet, Western diet
(WD), or Western diet
mixed with 2% ChTM for
11 weeks. The fourth
group of mice were fed WD
for 8 weeks, and then fed
WD containing 2% ChTM
for an additional 3 weeks.
All mice were fasted for 6
hours starting at 6 AM and
then killed. (A) Body
weight. (B) H&E staining of
liver sections. (C) Hepatic
triglyceride (TG) level. (D)
Hepatic FC and CE. (E)
Plasma total cholesterol.
(F) Analysis of bio-
energetics function of iso-
lated liver mitochondria
using the Seahorse XF
analyzer. All results
are expressed as means ±
SE (n ¼ 4). *Statistical sig-
niﬁcance vs chow-fed
controls. #Statistical sig-
niﬁcance vs WD-fed mice.
ADP, adenosine diphos-
phate; Anti-A, Antimycin A;
Chol, cholesterol; OCR,
oxygen consumption rate;
Oligo, Oligomycin.
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basal AKT and mTOR signaling, and that CYP7A1 over-
expression could strongly attenuate both basal and insulin
activation of AKT and mTOR. These results support a more
plausible explanation that increased ER cholesterol catabo-
lism somehow interfered with AKT activation at the PM.
Furthermore, because cholesterol in the membrane rafts is
known to be essential in PI3K/AKT activation32,33 and a
signiﬁcant amount of PM cholesterol trafﬁcs to the ER even
at basal conditions,42 it is even tempting to speculate that
increased CYP7A1-mediated ER cholesterol catabolism de-
creases the PM cholesterol pool, leading to attenuated AKTsignaling. It is well recognized that cholesterol dynamically
interacts with sphingolipids and phospholipids in various
membrane structures. Our analysis of the overall hepatic
lipid proﬁle further showed that CYP7A1 induction by ChTM
not only decreased FC, but also altered hepatic phospho-
lipids and sphingolipids. It is interesting to note that ChTM
feeding decreased many liver phospholipid species
(including phosphoatidylinositol) that serve as PI3K sub-
strates. In addition, liver sphingomyelins, which sequester a
pool of cholesterol in the PM, were higher in ChTM-fed mice.
Although the molecular basis for increased sphingomyelins
currently is unclear, it has been shown that cholesterol
Figure 9. ChTM restored
hepatic autophagy ﬂux in
Western diet–fed mice. The
experimental procedure
was the same as described
in Figure 8. (A) Western
blot: hepatic LC3B and
P62 protein levels. (B)
Some mice were injected
with Ad-RFP-GFP-LC3B at
108 pfu/mouse 3 days
before death. Mice were
brieﬂy fasted for 4 hours
staring at 6 AM before
death. Confocal micro-
scopy was used for the
analysis of LC3 ﬂuorescent
puncta in liver sections. The
average puncta number
was quantiﬁed manually in
approximately 40–80 cells/
group. Scale bar: 30 mm. (C)
Hepatic mRNA expression.
All results are expressed
as means ± SE (n ¼ 4).
*Statistical signiﬁcance vs
chow-fed controls. #Statis-
tical signiﬁcance vsWD-fed
mice. DAPI, 40,6-diamidino-
2-phenylindole.
- 2016 Bile Acid Sequestrant Induces Hepatic Autophagy 13depletion increased the abundance of sphingomyelins in
puriﬁed PM fractions of cultured cells in vitro.43 We report
ChTM-induced changes in phospholipid and sphingolipid
composition in mouse livers, and how such changes may
broadly affect various cellular signal transduction pathways
is worth further investigation. From a general perspective,
however, cells somehow may sense cellular cholesterol
levels to modulate mTOR activity, possibly because choles-
terol is an essential nutrient for cellular growth and func-
tion. Because cholesterol deﬁciency may be detrimental to
cell function and growth, autophagy activation upon
CYP7A1 induction may be an adaptive response to mobilize
stored cholesterol in the lipid droplets (Figure 10).Finally, this study provides proof-of-concept that tar-
geting the enterohepatic bile acid circulation induces he-
patic autophagy. Importantly, bile acid synthesis exclusively
occurs in the hepatocytes, which makes the identiﬁcation of
the CYP7A1–autophagy axis uniquely signiﬁcant. Clinically,
bile acid sequestrants have been used effectively to treat
hypercholesterolemia and improve insulin sensitivity.20
This should decrease the risk of cardiovascular disease,
the leading cause of mortality in patients with diabetes and
fatty livers. Current mechanistic understanding suggests
that bile acid sequestrants decrease LDL cholesterol by
targeting hepatic bile acid synthesis and LDL uptake, and
improve peripheral insulin sensitivity by inducing intestine
Figure 10. Proposed roles of hepatic bile acid metabolism
and autophagy in the regulation of cellular cholesterol
homeostasis. Hepatic cholesterol homeostasis is regulated by
the SREBP-2–dependent cholesterol-sensing mechanism.
Hepatic cholesterol accumulation inhibits SREBP-2 activity
and the expression of SREBP-2 target genes LDLR and
HMGCR, leading to reduced cholesterol uptake and de novo
cholesterol synthesis. In the ER, excessive FC is converted to
CE for storage in lipid droplets. This study suggests that
excessive hepatic FC accumulation impairs lysosome function
and inhibits autophagy. On the contrary, induction of CYP7A1
by ChTM causes increased ER cholesterol catabolism, relative
ER cholesterol depletion, and SREBP-2 activation, leading to
induction of LDLR and HMGCR expression to replenish
cellular cholesterol. This study showed that increased hepatic
CYP7A1 and decreased hepatic bile acids caused by ChTM
also induce autophagy, which may stimulate the hydrolysis of
CE in the lipid droplet (LD) via lipophagy, leading to increased
lysosomal FC transport to the ER as an adaptive response to
CYP7A1-induced ER cholesterol depletion.
14 Wang et al Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -glucagon-like peptide-1.44,45 This study suggests that in-
duction of hepatic autophagy by bile acid sequestrants also
may be beneﬁcial in improving cholesterol homeostasis and
insulin sensitivity. Similar to bile acid sequestrants, new
studies have shown that the potent and selective apical
sodium-dependent bile acid transporter inhibitors also
prevented hypercholesterolemia,21 improved insulin sensi-
tivity,46 and attenuated bile acid toxicity in cholestasis in
animal models.22,23 It may be interesting to test whether
apical sodium-dependent bile acid transporter inhibitors
could induce hepatic autophagy by the same principle.
Future studies will determine if targeting enterohepatic bile
acid signaling may have therapeutic implications in other
forms of genetic and acquired liver diseases that would
beneﬁt from selective induction of hepatic autophagy.References
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